Introduction: In heart failure and following myocardial infarction, plasma levels of TNF-α are elevated. The source of the cytokine is unknown. We hypothesized that the heart, itself, could be a source of TNF-α. Further, aspirin has recently been shown to block activation of the nuclear regulatory factor κB (NF-κB) which, in other systems, is involved in TNF-α gene transcription. We therefore tested the hypothesis that aspirin pretreatment would block TNF-α release from the heart. Methods: With IACUC approval, rats were anesthetized with pentobarbital. Hearts were removed and perfused Langendorf style at a constant pressure of 90 cm H2O with a buffer gassed with 95%O2/5%CO2. Following a 30 min. equilibration, LPS (100 ng/ml) was infused. At 30, 60, 90, 120, and 180 min. after initiation of LPS infusion, coronary flow was measured and coronary effluent analyzed for TNF-α and 6-keto-PGF1α. In other experiments, aspirin (2, 5 and 10 mM) or indomethacin (10 μM) was added to the perfusing buffer. TNF-α production is expressed as pg/min (concentration multiplied by flow). Data were analyzed by two-way ANOVA. Results: TNF-α was first detected at 90 min. after LPS and increased to max at 180 min. Aspirin (5 and 10 mM) inhibited LPS-stimulated TNF-α release (see Table). LPS-stimulated release of TNF-α was not affected by indomethacin. Both aspirin and indomethacin inhibited production of 6-keto-PGF1α. TNF-α Production by Isolated Heart (pg/min) Minutes 90 120 180 LPS 74±18 723±200 2442±600 LPS + 5 mM aspirin 157±75 675±160 1260±340*LPS + 10 mM aspirin 22±13*19±7*101±59*Values are mean ± s.d. N = 4 hearts/group.*= p<0.05 vs. LPS. Conclusion: Isolated rat hearts are a source of TNF-α. Pretreatment with aspirin significantly attenuates LPS-stimulated cytokine production. The mechanism of inhibition appears independent of cyclooxygenase blockade because both aspirin and indomethacin inhibited prostaglandin production but indomethacin had no effect on TNF-α production. A possible mechanism is inhibition of TNF-α gene transcription by aspirin blockade of NF-κB activation.
|Original language||English (US)|
|Journal||Critical care medicine|
|Issue number||1 SUPPL.|
|State||Published - Dec 1 1999|
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine